Extended Data Fig. 8: SAA is a downstream mediator of IL-6 signalling that drives myeloid cell accumulation and fibrosis within the liver.
From: Hepatocytes direct the formation of a pro-metastatic niche in the liver
a, Study design for b–d (n = 5 for all groups, except n = 4 for Saa−/− mice). b, Concentration of IL-6 in the serum collected from control mice (left), Il6−/− mice (middle), and Saa−/− mice (right) on indicated days. c, d, Images and quantification of pSTAT3+ cells, myeloid cells, fibronectin, and COL1. Arrows indicate Ly6G+ cells. Data representative of one experiment (a–d). e, Study design for f–h (n = 5 for mice injected with pLIVE-vector; n = 6 for mice injected with pLIVE-IL-6). f, Concentration of IL-6 in the serum. g, Images of the liver showing metastatic lesions (yellow, CK19) and Ki-67 (purple). h, Quantification of lesions (left) and Ki-67+ tumour cells (right). Data representative of one experiment (e–h). i, Study design for j (n = 5 for all groups, except n = 4 for Saa−/− mice injected with CCl4). j, Images and quantification of myeloid cells, fibronectin, and COL1. Arrows indicate Ly6G+ cells. Data representative of one experiment (i, j). Dashed lines indicate the lower limit of detection (b, f). Scale bars, 50 μm. Statistical significance calculated using two-tailed Mann–Whitney test (b, f, h) or one-way ANOVA with Dunnett’s test (other panels). NS, not significant. Data represented as mean + s.d. or mean ± s.d.
